Immuno-Oncology: where are we, and where to next?....
Just arrived in San Francisco to join almost 1,000 folks at the 2018 ASCO-SITC Symposium; …“this three-day meeting focuses on clinical and translational advances in immuno-oncology”. The Program promises to be very informative - a great opportunity to absorb up-to date details about IO in a broad setting, hear from recognized leaders in clinical trial design, development of PD-1 /PD-L1, CAR-T and vaccines. And perhaps apt timing with the recent ASCO-Post commentary on the new book: A Cure Within: Scientists Unleashing the Immune System to Kill Cancer. Exciting for me to have this opportunity.
As I look back to my own lymphoma diagnosis many years ago, and contrast the treatment options (across many cancers) then and now, and the scientific and clinical advances that have been (and are being) made, it is simply stunning, and absolutely remarkable to see what has been accomplished – and what is yet possible.
A huge debt owed to the many dedicated scientists, clinicians, patients and companies who collectively, in diverse ways, have invested to make this happen.